Details of OGTR monitoring and compliance activities during the quarter ended 31 December 2021
Clinical trial of a genetically modified (GM) chimeric Orthopoxvirus (CF33-hNIS) as a cancer treatment
Commercial supply of a genetically modified COVID-19 vaccine
This Communiqué covers matters considered at the 30th videoconference of the Gene Technology Technical Advisory Committee (28 April 2022).
Details of OGTR monitoring and compliance activities during the quarter ended 31 March 2022.
Commercial supply of a genetically modified vaccine against infectious laryngotracheitis virus in chickens
Regulatory approvals for activities with GMOs include two licence types based on whether or not they involve an intentional release of the GMO into the environment. Here is an explanation of what this means.
This Communique covers matters considered at the 16th meeting of the Gene Technology Ethics and Community Consultative Committee (24 June 2022).
This Communique covers matters considered at the 18th meeting of the Gene Technology Ethics and Community Consultative Committee (10 May 2023).
This document provides examples of the details you may need to supply in describing the information for which you are seeking declaration as CCI.